Bladder Cancer Weekly

December 23, 2024

Videos

Peer-to-Peer Clinical Conversations

Safety and Tolerability of TAR-200 Monotherapy in Patients with Bacillus Calmette-Guerin-Unresponsive High-Risk Non-Muscle-Invasive Bladder Cancer in SUNRISE-1 - Siamak Daneshmand

Siamak Daneshmand

Zachary Klaassen and Sia Daneshmand discuss the SunRISe-1 trial results examining TAR-200, a novel device that provides sustained release of gemcitabine in the bladder for BCG-unresponsive non-muscle invasive bladder cancer.

Utilizing Telehealth to Improve Access of Care of Patients with Bladder Cancer - Tracey Krupski

Tracey Krupski

Tracey Krupski explores the implementation of tele-cystoscopy to improve access to bladder cancer care in resource-challenged areas.

Beyond the Abstracts

Perioperative and Extended Outcomes of Patients Undergoing Parastomal Hernia Repair Following Cystectomy and Ileal Conduit - Beyond the Abstract

Histopathological, Molecular and Clinical Profiling of Lymphoepithelioma-Like Carcinoma of the Bladder (LELC-B) - Beyond the Abstract

Conference Coverage

SUO 2024: Sexual Dysfunction and Radical Cystectomy

SUO 2024: Emerging Therapeutics: Combination Therapy in Neoadjuvant Setting

SUO 2024: ABLE-32: A Randomized, Controlled, Phase IIIB Clinical Trial of Nadofarogene Firadenovec-vcng versus Observation in Patients with Intermediate-risk, Non-muscle Invasive Bladder Cancer

Articles

Editor Selected Abstracts and Commentaries

Bladder Cancer

FDA Approval Summary: Nadofaragene firadenovec-vncg for bacillus Calmette-Guérin-unresponsive non-muscle invasive bladder cancer.

Prospective Analysis of Confocal Laser Endomicroscopy for Assessment of the Resection Bed for Bladder Tumor.

Prognostic Value of a B Cell Exhaustion Gene Signature in Bladder Cancer - Expert Commentary

Developing and experimental validating a B cell exhaustion-related gene signature to assess prognosis and immunotherapeutic response in bladder cancer.

Bladder sparing management for muscle-invasive bladder cancer after a complete clinical response: ready for prime time?-a narrative review.

Impact of immigration background on feasibility of electronic patient-reported outcomes in advanced urothelial cancer patients.

Oncologic Outcomes of Sequential Intravesical Gemcitabine and Docetaxel Compared with Bacillus Calmette-Guérin in Patients with Bacillus Calmette-Guérin-Unresponsive Non-Muscle Invasive Bladder Cancer.

Low-cost and label-free blue light cystoscopy through digital staining of white light cystoscopy videos.

A multimodal deep-learning model based on multichannel CT radiomics for predicting pathological grade of bladder cancer.

Retrospective analysis of partial cystectomy in patients with muscle-invasive urothelial carcinoma: A German single-center experience.

The Role of Antibody-Drug Conjugates in Urothelial Cancer: A Review of Recent Advances in the Treatment of Locally Advanced and Metastatic Urothelial Cancer.

Phase II Trial of Risk-Enabled Therapy After Neoadjuvant Chemotherapy for Muscle-Invasive Bladder Cancer (RETAIN 1).

Racial differences in carcinoma-in-situ and non-muscle-invasive bladder cancer mortality: Accounting for insurance status, black segregation, and neighborhood poverty.

Perioperative immunotherapy in urothelial carcinoma: AMBASSADOR charts the path forward.

Impact of smoking exposure on disease progression in high risk and very high-risk nonmuscle invasive bladder cancer patients undergoing BCG therapy.

Benefits of Comprehensive Geriatric Assessment in Older Patients with Muscle-Invasive Bladder Cancer - Expert Commentary

CONNECT WITH US

Questions or Comments? Email us at editors@urotoday.com

Digital Science Press, LLC
2011 Phaethon Lane,
Reno, NV 89523

You are receiving this email because you have chosen to receive emails from UroToday.

Add us to your address book View this email as a web page Forward to a colleague Manage your subscriptions Unsubscribe

Copyright ©2024 Digital Science Press, LLC